The #1 Data Challenge for Pharmaceutical AI: Clinical and Regulatory Knowledge Complexity

By

Pharmaceutical companies generate enormous amounts of data: clinical trials, regulatory submissions, manufacturing records, commercial data, medical affairs information, pharmacovigilance reports.

AI promises to accelerate drug development, improve regulatory compliance, and optimize commercial operations. But pharma AI consistently struggles because the data is fragmented across domains with different languages and structures.

The Pharma Data Landscape

Pharmaceutical data includes:

R&D data: Discovery research, preclinical studies, formulation development Clinical data: Trial protocols, patient data, outcomes, adverse events Regulatory data: Submissions, approvals, labeling, post-market commitments Manufacturing data: Batch records, quality events, supply chain Commercial data: Sales, prescriptions, market data Medical affairs: Publications, KOL interactions, medical inquiries Safety data: Adverse event reports, signal detection, risk management

These domains evolved with different systems, different vocabularies, and different purposes. They don't share common identifiers or structures.

Why Pharma AI Fails

The Compound Identity Problem

A single drug candidate has multiple identifiers:

Research: "Compound XYZ-1234" Clinical: "ABC-001" Regulatory: "NDA 12345" Commercial: "BrandName™" Generic: "Active Ingredient Name"

When AI tries to answer "What do we know about this drug?", it needs to understand all these identifiers refer to the same compound.

A top-20 pharma company discovered their AI couldn't connect clinical trial data to commercial performance data for the same drug. Research used internal compound codes; commercial used brand names. The AI treated them as unrelated products.

Clinical Trial Complexity

Clinical trials generate complex, interconnected data:

Protocol relationships: Phase 1 → Phase 2 → Phase 3 progressions Study relationships: Parent studies, sub-studies, extensions Site relationships: Investigators, institutions, geographies Patient relationships: Cohorts, treatment arms, follow-up

AI that can't understand these relationships can't answer questions like "What's the complete development history for this indication?"

Regulatory Context

Drug development is governed by extensive regulatory context:

Regulatory precedent: How have similar drugs been treated? Labeling implications: What claims can be made based on evidence? Submission requirements: What's needed for approval in each market? Post-market obligations: What commitments exist after approval?

AI without regulatory knowledge gives answers that might be scientifically valid but regulatory non-starters.

Safety Signal Complexity

Pharmacovigilance requires connecting:

Adverse events to products to patients to outcomes

With complex causality assessment, temporal relationships, and regulatory reporting requirements.

A medical affairs team asked AI about a safety question. The AI returned clinical trial data but missed post-market safety reports filed in a different system. The incomplete answer could have led to wrong conclusions about the drug's safety profile.

Building Pharma Knowledge Layers

Pharma AI needs a knowledge graph that models:

Compound Entity Resolution

Unified compound identity across:

  • Research identifiers
  • Clinical identifiers
  • Regulatory identifiers
  • Commercial identifiers
  • Chemical identifiers (structures, names)

Every mention of a compound, regardless of identifier used, maps to canonical compound entity.

Development Program Structure

Relationships between:

  • Indications being pursued
  • Studies conducted (by phase, design, status)
  • Data generated
  • Regulatory interactions
  • Commercial launches

This enables queries like "What's the complete development history for Compound X in oncology?"

Regulatory Intelligence

Encoding of:

  • Regulatory requirements by market
  • Precedent from similar programs
  • Agency interactions and feedback
  • Labeling and approval status

This enables queries like "What regulatory precedent exists for this type of claim?"

Safety Signal Integration

Connection of:

  • Adverse event reports
  • Clinical trial safety data
  • Literature reports
  • Regulatory actions

With proper temporal and causality context.

Use Cases Enabled

With proper knowledge infrastructure:

Portfolio intelligence: "What's the status of all our oncology programs and how do they compare to competitor development?"

Requires connecting: compound entities → development programs → competitive intelligence, with accurate status across all identifiers.

Regulatory strategy: "Based on precedent, what's the likely FDA path for this indication?"

Requires: regulatory knowledge base with precedent analysis, connected to your compound's characteristics.

Safety assessment: "What's the complete safety profile for this compound across all sources?"

Requires: connecting clinical safety, post-market safety, literature reports for unified compound entity.

Medical affairs support: "What evidence supports this claim for healthcare provider discussions?"

Requires: connecting clinical data, publications, regulatory approvals for evidence synthesis.

Regulatory Considerations

Pharma AI has specific regulatory requirements:

21 CFR Part 11: Electronic records and signatures requirements Data integrity: ALCOA+ principles Validation: System validation requirements Audit trails: Complete traceability

The knowledge layer must be built with these requirements from the ground up.

Implementation Approach

For pharma companies building AI capability:

Start with Compound Master

Create unified compound identity:

  • Extract compound references from all systems
  • Map to canonical compound entities
  • Maintain identifier relationships

This alone enables significant AI improvement.

Add Development Context

Layer on development program structure:

  • Trial registry data
  • Internal tracking systems
  • Regulatory submission data
  • Commercial data

Incorporate External Knowledge

Integrate external sources:

  • Competitor intelligence
  • Literature databases
  • Regulatory precedent databases
  • Real-world evidence

Build Validation Framework

Ensure regulatory compliance:

  • Audit trails for all knowledge
  • Validation documentation
  • Change control processes
  • Source attribution

The Competitive Landscape

According to Deloitte's pharma R&D analysis, R&D productivity continues to decline across the industry. AI promises to reverse this trend—but only if it can access and understand the full knowledge landscape.

Companies that build effective knowledge infrastructure gain advantages:

  • Faster development timelines
  • Better regulatory outcomes
  • More efficient commercial operations
  • Improved safety monitoring

The Bottom Line

Pharma has the data. The challenge is turning fragmented, multi-domain data into unified knowledge that AI can use.

The knowledge layer approach—compound identity resolution, development program structure, regulatory intelligence, safety integration—provides the foundation for pharma AI that actually works.

See how Phyvant works for Healthcare → Book a call

Ready to make AI understand your data?

See how Phyvant gives your AI tools the context they need to get things right.

Talk to us